ArticleScientific reports2024
Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancer.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 23 citations in OpenAlex.
- Lymphocyte-to-monocyte ratio predicts survival in localized osteosarcoma in Vietnamese patients.iScience · 2026Article
- On-Treatment NLR Dynamics During CDK4/6 Inhibition Are Associated with Overall Survival in Metastatic Breast Cancer.Cancers · 2026Article
- Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade.Cancer immunology research · 2026Article
- Immunological biomarkers for precision stereotactic body radiation therapy in early-stage non-small cell lung cancer: a systematic review.EClinicalMedicine · 2026Article
- The predictive value of systemic inflammation response index and albumin-to-globulin ratio for prognosis in non-small cell lung cancer.Scientific reports · 2026Article
- Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001).Discover oncology · 2026Article
- Pretreatment and dynamic neutrophil-to-lymphocyte ratio in relation to CT-based volumetric response to platinum-based neoadjuvant chemotherapy in NSCLC.Biomolecules & biomedicine · 2026Article
- The Association Between Inflammatory Scores and Frailty Severity: An Exploratory Retrospective Analysis in Non-Small-Cell Lung Cancer Surgical Patients.Medical sciences (Basel, Switzerland) · 2026Article
- Neoadjuvant serplulimab combined with chemotherapy in locally advanced driver gene-negative squamous NSCLC: a multicenter observational study.Frontiers in immunology · 2026Observational
- Coordinated dynamics of circulating neutrophils, regulatory T lymphocytes, myeloid derived suppressor cells and distinct granulocytic subsets reveal a complex immune network in metastatic colorectal cancer.Frontiers in oncology · 2026Article
- Article
- A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC.CPT: pharmacometrics & systems pharmacology · 2025Article
- Tumour immune infiltration is independent of peripheral circulation of white blood cells in glioblastoma.Scientific reports · 2025Article
- Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Biomarker in Advanced Hepatocellular Carcinoma Treated with First-Line Immunotherapy.Journal of gastrointestinal cancer · 2025Article
- Variation in CBC-Derived Inflammatory Biomarkers Across Histologic Subtypes of Lung Cancer: Can Histology Guide Clinical Management?Diagnostics (Basel, Switzerland) · 2025Article
- Neutrophil-to-Lymphocyte Ratio in the Alzheimer's Disease Continuum.International journal of molecular sciences · 2025Review
- Prognostic Value of Systemic Immune Inflammation Index in Squamous Cell Lung Cancer.Journal of clinical medicine · 2025Article
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Journal for immunotherapy of cancer · 2025Article
- Prognostic significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in uterine carcinosarcoma.International journal of clinical oncology · 2025Article
- Single-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV.Oncology research · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory factors in the peripheral blood, such as the C-reactive protein level and neutrophil-to-lymphocyte ratio (NLR), are prognostic markers in multiple types of cancer, including non-small cell lung cancer (NSCLC). However, the association between inflammatory factors and prognosis based on histological types has not been adequately reported. In addition, the relationship between these factors and the immune condition of the tumor microenvironment (TME) is unclear. In this single center, retrospective study, we first investigated the relationship between preoperative inflammatory markers and clinical outcomes in 176 patients with NSCLC who underwent surgery. Lung adenocarcinoma (LUAD) showed no significant prognostic marker, whereas for lung squamous cell carcinoma (LUSC), a multivariate analysis showed that a high NLR was significantly associated with postoperative recurrence. In LUSC patients, the median time of postoperative recurrence-free survival in patients with a low NLR was longer than that in patients with a high NLR. We then compared the tumor-infiltrating lymphocyte (TIL) profile with inflammatory markers in peripheral blood and found that the NLR was negatively correlated with the frequencies of T cells and B cells in LUSC tissues. Thus, the NLR is a useful predictive biomarker for postoperative recurrence and may reflect the immune condition of the TME in LUSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.